Amyloid-β Degrader

Aleplastinin (PAZ-417) is an orally active, blood-brain barrier permeable, selective SERPINE1 (PAI-1) inhibitor (IC₅₀=655 nM). Aleplastinin activates the tissue type plasminogen activator (tPA)/fibrinolysis cascade by inhibiting PAI-1, thereby promoting the degradation of amyloid-β (Aβ) oligomers and monomers. Aleplastinin can significantly reduce plasma and brain Aβ levels, improve memory impairment, and reverse cognitive impairment. Aleplastinin can be used for research on Alzheimer's disease.

APP degrader-1 (Compound 0152) is an orally active amyloid precursor protein (APP) degrader that induces APP degradation and reduces the extracellular release of Aβ42. APP degrader-1 can bind to both CAPRIN1 and APP, and enhances their interaction as well as CAPRIN1-mediated APP degradation through the endosome-lysosome pathway.

CKR-49-17 is an activator of CK1γ2. CKR-49-17 decreases C99 and β-amyloid levels. CKR-49-17 can be used in the research of Alzheimer's disease (AD).

β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.

Alborixin is a polycyclic polyether ionophore Antibiotic. Alborixin is isolated from cultures of Streptomyces albus. Alborixin induces Autophagy via PTEN-mediated inhibition of the AKT pathway, thereby clearing Amyloid-β. Alborixin exhibits activity against Gram-positive bacteria and fungi. Alborixin can be used in the research of Alzheimer's disease.

SHR-1707 is a humanized anti-Aβ IgG1 monoclonal antibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).